Neurology News and Research

Latest Neurology News and Research

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

18 Mar 2010

Greatbatch Medical's OptiSeal Valved PTFE Peelable Introducer receives 510(k) clearance

Greatbatch Medical announced today that it has received regulatory clearance for its next generation valved peelable introducer used in the delivery of leads and catheters into the venous system. OptiSeal™ Valved PTFE Peelable Introducer achieved regulatory clearance on Monday, March 15, 2010, representing the first 510(k) regulatory approval under the Greatbatch Medical brand. It is also approved in Canada and CE marked for distribution in Europe.

17 Mar 2010

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study. The study was conducted in a healthy volunteer population of poor metabolizers of Cytochrome P450 2D6 (CYP2D6), an important enzyme involved in the metabolism of drugs. The study monitored the QTc interval following administration of a neurological treatment, which has been shown to have a higher drug exposure in poor metabolizers of CYP2D6.

From Parexel 17 Mar 2010

Cancer news coverage should also focus on hospice and end-of-life care

Newspaper and magazine reports about cancer appear more likely to discuss aggressive treatment and survival than death, treatment failure or adverse events, and almost none mention end-of-life palliative or hospice care, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

17 Mar 2010

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems. Now, a new report out of UCLA shows that the effects of prenatal methamphetamine exposure - or worse, a combination of methamphetamine and alcohol - may be even more damaging.

17 Mar 2010

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

Bovie Medical Corporation, a manufacturer and marketer of electrosurgical products, today announced its financial results for the fourth quarter and year ended December 31, 2009.

16 Mar 2010

BeaconEquity.com announces investment report featuring Intellipharmaceutics International

BeaconEquity.com announces an investment report featuring Intellipharmaceutics International Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

16 Mar 2010

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company’s approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix’s patent application, “Methods and Compositions for the Treatment of Neurological Disease,” which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain’s temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).

15 Mar 2010

DMC announces new agreements with Henry Ford West Bloomfield Hospital and Hurley Medical Center

Detroit Medical Center's Children's Hospital of Michigan has established new agreements with Henry Ford West Bloomfield Hospital and Hurley Medical Center in Flint to expand pediatric surgical expertise at these hospitals. As part of these agreements, pediatric surgeons from the Children's Hospital of Michigan are now performing outpatient surgical procedures and operations at these two health care facilities. In addition, the DMC has established a new Children's Hospital of Michigan Specialty Center at 5635 West Maple Road in West Bloomfield to house pediatric surgery services for patients.

15 Mar 2010

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

The U.S. Food and Drug Administration Neurological Devices Panel today voted seven to five to recommend approval with conditions of Deep Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. as adjunctive treatment for partial-onset seizures in adults with medically refractory epilepsy.

15 Mar 2010

Older patients receive potentially inappropriate medications when treated in emergency room: Study

A University of Michigan study recently published in Academic Emergency Medicine says that it is common for patients 65 and older to receive potentially inappropriate medications when treated in an emergency room.

15 Mar 2010

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Ipsen announced today the initiation of dosing in two phase II clinical studies to evaluate efficacy and safety of BIM 23A760 in two groups of patients, one suffering from carcinoid syndrome due to neuroendocrine tumors, the other from acromegaly.

15 Mar 2010

Study: Chromosomal microarray analysis detects genetic changes related to ASDs better than standard tests

A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about three times the detection rate for genetic changes related to autism spectrum disorders (ASDs) than standard tests. Publishing in the April issue of Pediatrics (and online March 15), the authors urge that CMA become part of the first-line genetic work-up for ASDs.

15 Mar 2010

Landmark clinical trial examines effective treatment options for childhood epilepsy

One of the oldest available anti-seizure medications, ethosuximide, is the most effective treatment for childhood absence epilepsy, according to initial outcomes published in this week's New England Journal of Medicine.

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Eisai Inc. today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute related to Eisai's GCPII (glutamate carboxypeptidase II) technology.

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Neurology News and Research

Latest Neurology News and Research

New specialty service at Montefiore Medical Center helps patients with drug allergies

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Greatbatch Medical's OptiSeal Valved PTFE Peelable Introducer receives 510(k) clearance

PAREXEL genotypes over 10,000 potential study participants to identify 400 CYP2D6 poor metabolizers

Cancer news coverage should also focus on hospice and end-of-life care

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

Bovie Medical reports revenues totalling $6.5M for fourth-quarter 2009

BeaconEquity.com announces investment report featuring Intellipharmaceutics International

Neurologix receives US PTO Notice of Allowance concerning treatment approach for epilepsy

DMC announces new agreements with Henry Ford West Bloomfield Hospital and Hurley Medical Center

FDA Neurological Devices Panel recommends approval of DBS Therapy for epilepsy

Older patients receive potentially inappropriate medications when treated in emergency room: Study

Ipsen commences dosing in two BIM 23A760 phase II studies for neuroendocrine tumors and acromegaly

Study: Chromosomal microarray analysis detects genetic changes related to ASDs better than standard tests

Landmark clinical trial examines effective treatment options for childhood epilepsy

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Neurology News and Research

Latest Neurology News and Research

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in